7 powodów, dla których warto zastosować awanafil w zaburzeniach erekcji Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2016
Słowa kluczowe:
zaburzenia erekcji, awanafil, leczenie
##plugins.themes.bootstrap3.article.main##
Abstrakt
Zaburzenia erekcji występują obecnie u bardzo dużej liczby mężczyzn. Wpływają one negatywnie na jakość ich życia, a u wielu z nich są pierwszym objawem zbliżającego się zawału mięśnia sercowego. W terapii zaburzeń erekcji lekami pierwszego rzutu są inhibitory fosfodiesterazy typu 5. Zalecenia Europejskiego Towarzystwa Urologicznego z 2015 r. rekomendują stosowanie inhibitorów PDE5, w tym awanafilu, który ze względu na swoje unikalne właściwości wyznacza nowy standard skuteczności i bezpieczeństwa w leczeniu zaburzeń erekcji.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kałka, D. (2016). 7 powodów, dla których warto zastosować awanafil w zaburzeniach erekcji . Medycyna Faktów , 9(3(32), 231-235. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2226
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90.
2. Eardley I.: The incidence, prevalence and natural history of erectile dysfunction. Sex. Med. Rev. 2013; 1: 13-16.
3. Kałka D., Domagała Z., Rakowska A. et al.: Modifiable risk factors for erectile dysfunction – an assessment of the awareness of such factors in patients suffering from ischemic heart disease. Int. J. Impot. Res. 2016; 28: 14-19.
4. Aytac I.A., McKinlay J.B., Krane R.J.: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84: 50-56.
5. Hatzimouratidis K., Eardley I., Giuliano F. et al.: Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. The Netherlands: European Association of Urology 2015 .
6. Awanafil. Charakterystyka produktu leczniczego. 2013.
7. Hellstrom W.J., Kaminetsky J., Belkoff L.H. et al.: Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study. J. Urol. 2015; 194(2): 485-492.
8. Levine G.N., Steinke E.E., Bakaeen F.G. et al.: Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2012; 125(8): 1058-1072.
9. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 2013; 34(38): 2949-3003.
10. Goldstein I., Jones L.A., Belkoff L.H. et al.: Avanafil for the treatment of erectile dysfunction: a multicenter randomized double-blind study in men with diabetes mellitus. Mayo Clin. Proc. 2012; 87: 843-852.
11. Mulhall J.P., Burnett A.L., Wang R. et al.: A phase 3, placebo-controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve-sparing radical prostatectomy. J. Urol. 2013; 189: 2229-2236.
12. Montorsi F., Briganti A., Salonia A. et al.: Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur. Eurol. 2003; 44: 360-364.
13. Mullhall J., King R., Glina S. et al.: Importance of and satisfaction with sex among men and women worldwide: results of the global better sex survey. J. Sex. Med. 2008; 5: 788-795.
2. Eardley I.: The incidence, prevalence and natural history of erectile dysfunction. Sex. Med. Rev. 2013; 1: 13-16.
3. Kałka D., Domagała Z., Rakowska A. et al.: Modifiable risk factors for erectile dysfunction – an assessment of the awareness of such factors in patients suffering from ischemic heart disease. Int. J. Impot. Res. 2016; 28: 14-19.
4. Aytac I.A., McKinlay J.B., Krane R.J.: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84: 50-56.
5. Hatzimouratidis K., Eardley I., Giuliano F. et al.: Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. The Netherlands: European Association of Urology 2015 .
6. Awanafil. Charakterystyka produktu leczniczego. 2013.
7. Hellstrom W.J., Kaminetsky J., Belkoff L.H. et al.: Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study. J. Urol. 2015; 194(2): 485-492.
8. Levine G.N., Steinke E.E., Bakaeen F.G. et al.: Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2012; 125(8): 1058-1072.
9. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 2013; 34(38): 2949-3003.
10. Goldstein I., Jones L.A., Belkoff L.H. et al.: Avanafil for the treatment of erectile dysfunction: a multicenter randomized double-blind study in men with diabetes mellitus. Mayo Clin. Proc. 2012; 87: 843-852.
11. Mulhall J.P., Burnett A.L., Wang R. et al.: A phase 3, placebo-controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve-sparing radical prostatectomy. J. Urol. 2013; 189: 2229-2236.
12. Montorsi F., Briganti A., Salonia A. et al.: Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur. Eurol. 2003; 44: 360-364.
13. Mullhall J., King R., Glina S. et al.: Importance of and satisfaction with sex among men and women worldwide: results of the global better sex survey. J. Sex. Med. 2008; 5: 788-795.